All In Biotech

Drug Trial Radar · NCT06141980

Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

A Multi-center, phase3, Open-label Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Gemigliptin

Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

134

Planned (sponsor's estimate)

Start

Dec 2023

Primary completion

Sep 2025

Study completion Sep 2025

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period. At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial. The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

  • DWP16001 0.3 mgDrug

    DWP16001 0.3mg, Tablets, Orally, Once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety outcomes_Adverse events occurred during clinical trialsTime frame: from baseline up to 52 weeks
  2. Safety outcomes_ Change of blood pressureTime frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP
  3. Safety outcomes_ Change of heartbeatTime frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP
  4. Safety outcomes_ Change of body temperatureTime frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP
  5. Efficacy outcome_Change of HbA1cTime frame: from Baseline at Week 8, 16, 24, 38, and 52 after administration of the IP
  6. Efficacy outcome_Change of FPGTime frame: from baseline at Week 8, 16, 24, 38, and 52 after administration of the IP
  7. Efficacy outcome_Proportion of subjects achieving HbA1c target of < 6.5%Time frame: at Weeks 8, 16, 24, 38 and 52 after administration of the IP
  8. Efficacy outcome_Proportion of subjects achieving HbA1c target of < 7.0 %Time frame: at Weeks 8, 16, 24, 38 and 52 after administration of the IP

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.